These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

347 related articles for article (PubMed ID: 20501857)

  • 1. Histone methyltransferase gene SETD2 is a novel tumor suppressor gene in clear cell renal cell carcinoma.
    Duns G; van den Berg E; van Duivenbode I; Osinga J; Hollema H; Hofstra RM; Kok K
    Cancer Res; 2010 Jun; 70(11):4287-91. PubMed ID: 20501857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of tumor suppressor genes apart from VHL on 3p by deletion mapping in sporadic clear cell renal cell carcinoma (cRCC).
    Singh RB; Amare Kadam PS
    Urol Oncol; 2013 Oct; 31(7):1333-42. PubMed ID: 21962529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Studies on Primary Tubular Epithelial Cells Indicate a Tumor Suppressor Role of SETD2 in Clear Cell Renal Cell Carcinoma.
    Li J; Kluiver J; Osinga J; Westers H; van Werkhoven MB; Seelen MA; Sijmons RH; van den Berg A; Kok K
    Neoplasia; 2016 Jun; 18(6):339-46. PubMed ID: 27292023
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Chiang YC; Park IY; Terzo EA; Tripathi DN; Mason FM; Fahey CC; Karki M; Shuster CB; Sohn BH; Chowdhury P; Powell RT; Ohi R; Tsai YS; de Cubas AA; Khan A; Davis IJ; Strahl BD; Parker JS; Dere R; Walker CL; Rathmell WK
    Cancer Res; 2018 Jun; 78(12):3135-3146. PubMed ID: 29724720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma.
    Xiang W; He J; Huang C; Chen L; Tao D; Wu X; Wang M; Luo G; Xiao X; Zeng F; Jiang G
    Oncotarget; 2015 Feb; 6(6):4066-79. PubMed ID: 25714014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
    Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
    Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.
    Li L; Miao W; Huang M; Williams P; Wang Y
    Mol Cell Proteomics; 2019 Mar; 18(3):437-447. PubMed ID: 30487242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic reprogramming of DNA methylation in SETD2-deregulated renal cell carcinoma.
    Tiedemann RL; Hlady RA; Hanavan PD; Lake DF; Tibes R; Lee JH; Choi JH; Ho TH; Robertson KD
    Oncotarget; 2016 Jan; 7(2):1927-46. PubMed ID: 26646321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
    Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
    Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and Mutation Patterns of PBRM1, BAP1 and SETD2 Mirror Specific Evolutionary Subtypes in Clear Cell Renal Cell Carcinoma.
    Bihr S; Ohashi R; Moore AL; Rüschoff JH; Beisel C; Hermanns T; Mischo A; Corrò C; Beyer J; Beerenwinkel N; Moch H; Schraml P
    Neoplasia; 2019 Feb; 21(2):247-256. PubMed ID: 30660076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
    Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Su X; Zhang J; Mouawad R; Compérat E; Rouprêt M; Allanic F; Parra J; Bitker MO; Thompson EJ; Gowrishankar B; Houldsworth J; Weinstein JN; Tost J; Broom BM; Khayat D; Spano JP; Tannir NM; Malouf GG
    Cancer Res; 2017 Sep; 77(18):4835-4845. PubMed ID: 28754676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of expression of the DRR 1 gene at chromosomal segment 3p21.1 in renal cell carcinoma.
    Wang L; Darling J; Zhang JS; Liu W; Qian J; Bostwick D; Hartmann L; Jenkins R; Bardenhauer W; Schutte J; Opalka B; Smith DI
    Genes Chromosomes Cancer; 2000 Jan; 27(1):1-10. PubMed ID: 10564580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis.
    Velickovic M; Delahunt B; McIver B; Grebe SK
    Mod Pathol; 2002 May; 15(5):479-85. PubMed ID: 12011252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis.
    Dreijerink K; Braga E; Kuzmin I; Geil L; Duh FM; Angeloni D; Zbar B; Lerman MI; Stanbridge EJ; Minna JD; Protopopov A; Li J; Kashuba V; Klein G; Zabarovsky ER
    Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7504-9. PubMed ID: 11390984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: molecular diagnostics and possible targets for personalized therapies.
    Piva F; Santoni M; Matrana MR; Satti S; Giulietti M; Occhipinti G; Massari F; Cheng L; Lopez-Beltran A; Scarpelli M; Principato G; Cascinu S; Montironi R
    Expert Rev Mol Diagn; 2015; 15(9):1201-10. PubMed ID: 26166446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic profiling of the genes on chromosome 3p in sporadic clear cell renal cell carcinoma.
    Togo Y; Yoshikawa Y; Suzuki T; Nakano Y; Kanematsu A; Zozumi M; Nojima M; Hirota S; Yamamoto S; Hashimoto-Tamaoki T
    Int J Oncol; 2016 Apr; 48(4):1571-80. PubMed ID: 26891804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma.
    Ho TH; Park IY; Zhao H; Tong P; Champion MD; Yan H; Monzon FA; Hoang A; Tamboli P; Parker AS; Joseph RW; Qiao W; Dykema K; Tannir NM; Castle EP; Nunez-Nateras R; Teh BT; Wang J; Walker CL; Hung MC; Jonasch E
    Oncogene; 2016 Mar; 35(12):1565-74. PubMed ID: 26073078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12.
    González-Rodríguez P; Engskog-Vlachos P; Zhang H; Murgoci AN; Zerdes I; Joseph B
    Cell Death Dis; 2020 Jan; 11(1):69. PubMed ID: 31988284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.